Forkhead box O class transcription factors are homeostasis regulators that control cell death, longevity and therapy-resistance. In neuroblastoma (NB), nuclear FOXO3 correlates with stage M disease and poor prognosis. To analyze whether FOXO3 contributes to drug-resistance in this childhood cancer, we investigated how different high-stage-derived NB cells respond to the activation of an ectopic FOXO3 allele. We found endogenous FOXO3 mostly localized to the nucleus-upon activation of an ectopic, 4OHTactivated FOXO3(A3)ER fusion protein two of the cell lines underwent apoptosis, whereas in the others FOXO3-activation even increased survival during drug-treatment. In the latter cell type, FOXO3 did not induce the BH3-only protein BCL2L11/BIM due to impaired binding of FOXO3 to the BIM-promoter, but still activated other FOXO3 targets. It was shown before that FOXO3 and TP53 physically interact with each other at two different regions-the TP53-N-terminus binds to the FOXO3-DNA binding domain (DBD) and the FOXO3-C-terminus interacts with the TP53-DBD. Interestingly, cell lines that undergo FOXO3-induced cell death carry homozygous point mutations in the TP53-DBD near the structural hotspot-mutation-site R175H, which abrogated FOXO3-TP53 interaction. In contrast, in FOXO3-death-resistant cells no point mutations in the TP53-DBD were found-in these cells FOXO3-TP53 complexes are formed and FOXO3-binding to the BIM-promoter, but not the induction of the detoxifying protein SESN3, were prevented, which in turn increased chemo-protection in this type of high-stage-derived NB cells. Our combined data suggest that FOXO3 steps in as a death inducer in case of TP53-mutation, whereas functional TP53 alters FOXO3-target-promoter-recognition, which prevents death induction by FOXO3 and instead increases chemo-protection and survival of NB cells. This novel mechanism may explain the low incidence of TP53 mutation in high-stage NB at diagnosis and suggests FOXO3 as a therapeutic target for this childhood malignancy.
INTRODUCTION
The mammalian forkhead box O (FOXO) transcription factor family consists of four members, FOXO1/FKHR, FOXO3/FKHRL1, FOXO4/ AFX and FOXO6, which are involved in multiple cellular processes ranging from apoptosis induction to longevity. 1 FOXO3-mediated cell death in neuroblastoma (NB), an aggressive childhood tumor that develops form precursor cells of the neural crest during embryogenesis, 2 has been associated with induction of the proapoptotic BH3-only proteins B-cell-lymphoma-gene-2-like-11 (BCL2L11/BIM), phorbol-12-myristate-13-acetate-induced-protein-1 (PMAIP1/NOXA) and repression of pro-survival BCL2-like-1 (BCL2L1/BCLXL) and the baculoviral-inhibitor-of-apoptosisrepeat-containing-5 (BIRC5/survivin) and is modulated by the ROS-regulating chromosome-10-open-reading-frame-10-protein (C10ORF10/DEPP). [3] [4] [5] [6] [7] FOXO3-activity is mainly regulated by posttranslational modifications (reviewed in Ausserlechner et al. 8 and Hagenbuchner and Ausserlechner 9 ), resulting in changes of its cellular localization or affecting its binding to DNA or proteins. Protein-kinase-B (PKB) which is frequently hyper-activated in highstage NB due to aberrant expression of the brain-derivedneurotrophic-factor and its cognate receptor NTRK2/TRKB 10 directly phosphorylates FOXO3 causing association with 14-3-3 proteins, nuclear exclusion and transcriptional inactivation of FOXO3 in malignant NB cells. 5, [11] [12] [13] We previously demonstrated that in patient biopsies FOXO3 localizes to the nucleus even when phosphorylated at the PKB-site threonine-32. 14 Stress conditions, such as chemotherapy, override growth-factor-mediated phosphorylation/inactivation of FOXO3 by PKB, which results in the relocation of FOXO3 to the nucleus. 3, 9 FOXO3 was initially considered as a tumor suppressor by inducing apoptosis or cell-cycle-arrest. 15 However, the opposed function of FOXO3 in cellular detoxification, 6, 16 the development of drug-resistance 17, 18 and the feedback-regulation on PKB-activity 19 uncovered an additional, tumor-promoting role of FOXO3.
Beside post-translational modifications FOXO3's activity can also be influenced by co-factor binding. One binding partner of FOXO3 is the tumor protein TP53/p53 which is mutated in over 50% of cancer types. 20 In NB, however, mutations of TP53 are rare at diagnosis (less than 2% of patients), but frequent loss of function is observed in relapsed tumors. 21 FOXO3 and TP53 share numerous target genes such as CDKN1/P21CIP1, GADD45A or BBC3/PUMA; hence, they are involved in the same cellular processes like cell-cycle-arrest, DNA-damage-repair and apoptosis. [22] [23] [24] [25] In this study, we discovered that in patient-derived, high-stage NB cells that express wild-type TP53, FOXO3 interacts with TP53, which prevents the binding of FOXO3 to the BIM-promoter and FOXO3-induced cell death. In these cells, FOXO3-activation even enhances the resistance to chemotherapy via increased expression of SESN3.
RESULTS
High-stage NB cell lines differentially respond to active FOXO3 FOXO transcription factors are substrates of the phosphatidylino-sitol3-kinase-PKB-signaling-pathway and phosphorylation by PKB triggers nuclear export and functional inactivation of these transcription factors (reviewed in Arden and Biggs 26 ). We demonstrated before that in NB cells FOXO3 is frequently PKBphosphorylated and that especially in high-stage-derived NB cells FOXO3 partially localizes to the nucleus despite highly active PKB (Figures 1a and c, Supplementary Figures S1a and c) . 14, 27 In these cells, oxidative stress and DNA-damage further increase the amount of nuclear FOXO3, suggesting that the cell-stressdependent regulation of FOXO3 is still functional (Figure 1c ). To further analyze FOXO3-function in high-stage NB cells, we used an ectopically expressed 4OHT-inducible, PKB-phosphorylationindependent FOXO3(A3)ER fusion-protein and infected highstage NB1, NB3, NB4, NB8 and NB15 cells. 14, 28 The expression and translocation of ectopic Figure S3 ). In resistant NB4/FOXO3 or NB8/FOXO3 cells, however, BIM was not regulated at all. A slight repression of BCLXL and survivin was observed in NB8/FOXO3 cells on protein-, and in NB4/ FOXO3 on mRNA-level (Figure 2a and Supplementary Figure S3 ), suggesting that induction of pro-apoptotic BIM might induce a feed-forward-regulation, for example via accumulation of ROS that further increases target-gene-regulation and drives cells into death. The ROS-detoxifying enzyme SESN3 and the cell-cycleregulator CDKN1B/P27KIP1, both bona-fide targets of FOXO3, 29, 30 were induced in all three cell lines, which is also a proof that the ectopically expressed FOXO3 allele is active and functional (Figures 2a and b) .
To analyze whether the lack of transcriptional regulation of apoptosis-regulatory targets might be related to impaired promoter-binding, we performed chromatin-immunoprecipitation experiments and investigated whether FOXO3 differentially binds to the BIM-, NOXA-and SESN3-promoter in NB15/FOXO3 and NB8/ FOXO3 cells. Activation of ectopic FOXO3 increased the amount of FOXO3 at the BIM-promoter more than threefold in NB15/FOXO3 cells, whereas no changes in FOXO3-binding were detected in NB8/FOXO3 cells ( Figure 2c ). In contrast, in both cell lines significantly increased FOXO3-binding to the SESN3-promoter was detectable ( Figure 2c ), correlating with mRNA and protein levels (Figures 2a and b ) and also FOXO3-binding to the NOXApromoter was increased in both cell lines (Figure 2c ). This suggests that in resistant NB8/FOXO3 cells FOXO3 does not bind to the BIM-promoter upon activation, but still activates other transcriptional targets.
We demonstrated previously that BIM-induction by FOXO3 triggers a biphasic ROS-accumulation, which critically regulates cell death-induction by FOXO3-activation and/or by addition of DNA-damaging agents in NB. 3, 31 The primary ROS-wave is detected after 12 h post FOXO3-activation, the second, much more pronounced ROS-wave reaches a climax between 36 and 48 h after FOXO3-activation in NB15/FOXO3 cells. 3 (Figure 2a ), etoposide-treatment induced BIM only in NB15 cells, but not in NB4 or NB8 cells ( Figure 3b ). As a control for the relevance of FOXO3 in this process, we included NB15/shFOXO3-17 cells with constitutive knockdown of FOXO3 by shRNAexpression. In these cells, induction of BIM by etoposide ( Figure 3b ) and ROS accumulation 3 is completely prevented, proving that etoposide leads to induction of BIM and further ROS via FOXO3. ROS-levels, as measured by MitoTrackerRed (CM-H 2 XROS) staining, were markedly induced in NB15 cells, completely absent in NB4 cells and only a faint, statistically not significant increase was observed in NB8 cells upon etoposide treatment, correlating with the lack of BIM regulation in the resistant cells. Taken together our results suggest that resistance to FOXO3-induced apoptosis in high-stage NB cells correlates with the absence of BIM-induction.
Promoter-binding of transcription factors can be influenced by promoter-methylation, post-translational modifications or interaction with distinct co-factors. To analyze whether one of these conditions affects FOXO3-binding to the BIM-promoter, we performed MethyLight PCR in cells treated with 4OHT and 5-Aza-2′-deoxycytidine (5-azadC, positive control). However, we did not detect any DNA-methylation of the classical BIM-promoter region in NB4/FOXO3, NB8/FOXO3 and NB15/FOXO3 cell lines compared to a methylated control gene (data not shown) and an alternative BIM-promoter (BIM_02; described in Gaviraghi et al. 32 ) was only methylated in NB8/FOXO3 and NB15/FOXO3 cells, but not in NB4/FOXO3 cells (Supplementary Figure S4a ). Therefore, methylation of the alternative BIM-promoter does not correlate with the apoptosis-resistance-phenotype in NB4/FOXO3 and NB8/ FOXO3 cells.
The deacetylation of FOXO3 by sirtuins has been described to significantly influence target-gene-regulation by FOXO3. [33] [34] [35] However, the results in Supplementary Figure S4b did not reveal any differences in the acetylation-status of FOXO3, suggesting that overall acetylation/deacetylation of FOXO3 is not responsible for the observed phenotype. The transcriptional activity of FOXO3 is steered by physical interaction with TP53. Co-factor-binding can significantly modulate target-gene-regulation of transcription factors. At diagnosis, mutations of TP53 are rare and loss-of-function mutations are mostly detected in relapsed NB-tumors, which then correlate with increased chemotherapy-resistance. 21, 36 Wild-type TP53 is usually hardly detectable due to the short half-life of this protein, but accumulates during DNA-damage. Elevated TP53 levels in the absence of genotoxic stress therefore suggest a mutation of the TP53 gene. 37 When treating NB cells with increasing concentrations of etoposide, NB4 and NB8 cells underwent cell death at lower doses than NB15 cells suggesting reduced sensitivity of NB15 cells to DNA-damaging agents ( Figure 4a ). By immunoblot analyses we observed different TP53-levels in high-stage NB cell lines. In FOXO3-resistant NB1, NB4 and NB8 cells TP53-expression was hardly detectable, whereas increased steady-state expression of TP53 was visible in NB3 and NB15 cells suggesting TP53mutation ( Figure 4b ). Consequently, we sequenced the entire coding-region of TP53 and discovered that NB3 and NB15 cells carry homozygous mutations in the DBD of TP53. The G → T mutations at codon 172 (Val4Phe) in NB15 cells and at codon 176 (Cys4Phe) in NB3 cells flank the structural hotspot mutation R175H frequently found in advanced cancer 38 (Figure 4c ). The R175H mutation affects the TP53-conformation and hampers the TP53/ATM DNA-damage response. To test, whether the mutations found in NB3 and NB15 cells alter target-gene-induction by TP53, we induced DNA-damage-response by etoposide-treatment. In both subtypes, TP53 still significantly accumulated after etoposide-treatment: in NB1, NB4 and NB8 cells a three-to-nine-fold induction of the TP53 bona fide targets CDKN1A/P21CIP1 and 39 whereas in NB3 and NB15 cells P21CIP1 was marginally induced and PUMA was not induced at all (Figure 4d ). This suggests that the point-mutations in the DNA-binding-domain of TP53 in NB3 and NB15 cells impair transcriptional-activation of TP53 target-genes. Sequencing also revealed a TP53-base-exchange at codon 72 (C → G) in the linker region between the transactivating domain and the DBD in NB4 (heterozygous), NB1, NB8 and NB15 cells (homozygous) that was not seen in NB3 cells (Supplementary Figure S5 ). This represents a polymorphism which was described to correlate with increased risk for certain forms of cancer 40 -the relevance for NB development is not clear. A physical interaction of the CR3-region and the forkhead (FH) domain of FOXO3 with the TP53-DBD that affects the activity of both transcription factors has been demonstrated before. 41, 42 To investigate, whether the identified mutations in the TP53-codingregion differentially affect FOXO3-TP53-interaction in NB, we performed co-immunoprecipitation experiments. FOXO3 binds to TP53 in NB4 and NB8 cells after etoposide-treatment, but not in NB15 cells (Figure 4e ). This suggests that the V172F-mutation in NB15 cells affects hetero-dimerization with FOXO3 and that FOXO3-TP53-complexes in NB4 and NB8 cells might interfere with distinct target-promoter-binding. To proof this hypothesis, we performed chromatin-immunoprecipitation-analyses on FOXO3- binding to the target-promoters BIM, NOXA and SESN3 in response to etoposide-treatment. We observed increased FOXO3-binding to the BIM-promoter in NB15 cells after 2 h of etoposide-treatment, which was not visible in NB8 cells (Figure 4f ), correlating with the results of the immunoblot analyses in Figure 3b . A slightly increased binding to the SESN3-promoter was seen in NB8 cells, whereas binding of FOXO3 to the NOXA-promoter showed similar increase by etoposide-treatment in both cell lines ( Figure 4f ). These results reflect the FOXO3-target-promoter-interaction previously observed with the FOXO3(A3)ERtm allele (Figure 2c ). Also mRNA-regulation of these genes in response to etoposidetreatment showed induction of all three target genes only in NB15 cells, whereas in NB4 and NB8 cells only NOXA-levels increased (Supplementary Figure S6) . Taken together, these data imply that under genotoxic stress FOXO3 forms a complex with TP53 in NB4 and NB8 cells, which prevents FOXO3-binding to the BIM-promoter and induction of BIM-protein, whereas the NOXApromoter contains a TP53 binding site and hence FOXO3 may be recruited via TP53 to this promoter and sequestered away from the SESN3-promoter. In NB15 cells, however, the specific mutation of TP53 alters the interaction between FOXO3 and TP53 (Figure 4d ), so that non-sequestered FOXO3 binds to the BIMpromoter ( Figure 4f ) and induces BIM-expression in response to etoposide-treatment (Figure 3b, Supplementary Figure S6 ).
FOXO3-induced drug-protection depends on functional TP53 and SESN3
To investigate how TP53/FOXO3 complexes in NB4 and NB8 cells affect the response to chemotherapy we performed colonyformation-assays to determine clonogenic-survival of these cells after exposure to chemotherapeutic agents. Ectopic FOXO3activation in the FOXO3-responsive NB3 and NB15 cells leads to less colony-formation compared to control cells, but in presence of chemotherapeutics higher doses of etoposide and doxorubicin were needed to significantly reduce colony-formation capacity in these cells (Figure 5a Figure S8c) 3 was able to increase drug-sensitivity only in NB8 cells, but not in NB15 cells (Figure 5d ). The pro-survival phenotype of FOXO3 was also visible in 3D-tumor-spheroids, where FOXO3activation significantly increases spheroid-size and viability as measured by ATP-content (Figure 5e ).
Since ectopic FOXO3 binds to the SESN3-promoter and induces its transcription (Figures 2b and c) we studied whether the FOXO3-mediated pro-survival phenotype during chemotherapy might involve SESN3. Therefore, we knocked-down SESN3 by shRNA and analyzed colony-formation. Knockdown of SESN3 was verified by qRT-PCR (Supplementary Figure S8a) and significantly reduced the chemo-protective effect of FOXO3 in NB8/FOXO3-shSESN3 cells (Figure 5b) . Consistent with the slightly less efficient knockdown in NB4/FOXO3-shSESN3 cells drug-resistance was also reduced to a lesser extent in this second cell line and increased basal resistance of FOXO3-transgenic cells was completely abrogated (Figure 5c ). Drug-treatment in these SESN3knockdown cells also led to significantly increased ROSaccumulation ( Supplementary Figure S8b ), suggesting that ROSinduction by FOXO3 might be re-activated in these cells. This implies that SESN3 contributes to FOXO3-mediated drug-protection in NB4 and NB8 cells.
To determine whether TP53-FOXO3 interaction is critical for the lack of BIM-induction, we repressed TP53 by short-hairpin RNA against TP53 and verified the knockdown by immunoblot after 2 h of etoposide-treatment (Figures 6a and d) . Interestingly, the knockdown of TP53 partially restored etoposide-triggered BIMinduction and abrogated the FOXO3-imposed drug-protectionphenotype in NB8/FOXO3 and in NB4/FOXO3 cells. The efficient knockdown of functional TP53 was reflected by the increased basal resistance to chemotherapeutic drugs similar to NB15 cells (Figures 6c and e ). Finally, we amplified the mutated TP53-codingsequence from NB15-cDNA and cloned it downstream of EYFP into a retroviral vector. After infection of NB8 and NB8/FOXO3 cells the expression of the EYFP-TP53mut-fusion-protein was verified by immunoblot ( Figure 6b ). As for TP53-knockdown, expression of TP53-V172F-protein increased basal drug-resistance, but impaired the FOXO3-imposed pro-survival phenotype (Figure 6c ), proving that the disruption of FOXO3-TP53-complexes by this mutation abrogates the FOXO3-induced drug-protection in NB cells.
DISCUSSION
Tumor promotion by FOXO3 has been discussed for several years. 17, 19, [43] [44] [45] [46] Here, we identified a subtype of NB cells, where FOXO3-activation protected the cancer cells against DNAdamaging chemotherapeutic agents. The drug-resistance was mainly regulated by the interaction between wild-type TP53 and FOXO3, which alters FOXO3-promoter-recognition. Hyperactivation of the phosphatidylinositol3-kinase/PKB signaling pathway frequently observed in NB is associated with FOXO3inactivation and its re-localization into the cytoplasm. 4, 5, [11] [12] [13] However, in high-stage-derived NB cell lines FOXO3 partly localizes to the nucleus despite high PKB-activity and regulates (Figure 1e and Supplementary Figure S2 ). These Analyses of target-gene-regulation uncovered that the apoptosis-inducing gene BIM which is critical for deathexecution after FOXO3-activation in NB cells 3, 5, 47 was not induced in NB4/FOXO3 and NB8/FOXO3 cells. Other FOXO3-targets were still regulated in these cells, although in part to a lesser extent (Figures 2a and b and Supplementary Figure S3 ). The nuclear accumulation of FOXO3 and the induction of P27KIP1, however, demonstrate that the ectopic FOXO3(A3)ERtm construct was active in all cell lines. Since BIM is the key player in FOXO3induced death that triggers ROS-accumulation, 3 the lack of BIMregulation might be crucial for absence of FOXO3-induced death. The transcriptional activity of FOXO3 is strongly affected by posttranslational modifications. Deacetylation by sirtuins reprograms the activity of FOXO3 at oxidative stress conditions towards prosurvival target genes, like SOD2 and GADD45A instead of BIM and P27KIP1. 48 However, we did not observe significant differences in the FOXO3-acetylation-status between resistant and sensitive cell lines (Supplementary Figure S4b) . This most likely excludes acetylation/deacetylation of FOXO3 as a critical factor for Figure S4a , Supplementary Table S4 ) and methylation-patterns of an alternative BIM-promoter did not correlate with the resistance-phenotype, we also excluded differential-methylation as the cause for lack of BIM-induction in NB4 and NB8 cells. The N-terminus of TP53 binds to the FH-domain of FOXO3 and in parallel the CR3-domain of FOXO3 interacts with the DBD of TP53, 41 which alters target-recognition by FOXO3. 42 Inhibition of one of these two interaction-interfaces, for example, of the TP53-DBD/FOXO3-CR3-region, prevents complex formation. We observed that TP53 and FOXO3 form complexes in the FOXO3resistant NB-subtype (NB4 and NB8) upon exposure to etoposide, but not in the FOXO3-sensitive NB-subtype (NB15, Figure 4e ), which might be explained by the TP53 mutations V172F (NB15) and C176F (NB3) (Figure 4c ). These mutations reduce TP53transcriptional-activity as demonstrated by reduced P21CIP1 and PUMA-induction after DNA-damage ( Figure 4d ) and prevent its interaction with FOXO3 (Figure 4e ), whereas the polymorphism at codon 72 (C → G) ( Supplementary Figure S5 ) did not have an effect (Figure 4d ). Many inactivating mutations of TP53 have been described also in NB, 36 but to our knowledge not for V172F. TP53-V172F was recently described as a temperature-sensitive TP53 mutant that affects cisplatin-sensitivity in ovarian cancer. 49 However, V172F and C176F flank the structural hotspot mutation locus R175H in the Zn 2+ -binding region that changes TP53conformation. R175H is the most common mutation found in human cancer that impairs DNA-binding and ATM-mediated DNAdamage-response, thereby leading to genetic instability and defective G2/M checkpoint control. 50 Further analyses on how this TP53/FOXO3-complex affects cell-fate uncovered drugprotection by FOXO3-activation, whereas knockdown of endogenous FOXO3 increased drug-sensitivity ( Figure 5 ). This is in line with several studies which already identified correlations between FOXO3 and drug-resistance in different cancer types. [17] [18] [19] 43, 44 Detailed analyses of target-gene-regulation after FOXO3activation by etoposide or direct activation of the FOXO3(A3) ERtm-protein uncovered that BIM is not induced in resistant cell lines, whereas NOXA was induced in both, FOXO3-resistant and -sensitive cell types (Figures 2, 3b and 4f ). Although FOXO3 binds to the SESN3-promoter and induces SESN3 after 4OHT-activation, only partial increase in SESN3-promoter-binding or SESN3induction were observed in chemo-resistant NB4 and NB8 cells after etoposide-treatment. One explanation is that during DNAdamage, endogenous FOXO3 is sequestered by accumulating functional TP53, thereby also preventing further binding to the SESN3-promoter. Figure 6 ), our data suggest that NB1, NB4 and NB8 cells benefit from nuclear/active FOXO3 by already elevated SESN3-expression, which allows survival even under high-stress conditions after DNA-damage. We demonstrated before that SESN3 mediates ROS-detoxification in NB15 cells, 3 but this protective effect is overcome by continuous mitochondrial damage via BIM, which eventually leads to death in these cells (Figure 1e ). 3 In FOXO3-resistant cells, however, endogenous TP53 forms a complex with FOXO3, which prevents BIM-induction. In summary, our data describe a pro-survival function of FOXO3 in high-stage NB which depends on distinct target-generegulation under low-and high-stress conditions (Figure 7) . In NB, TP53-mutations are rare and mainly detected in biopsies from relapsed patients. Our study uncovered that wild-type TP53 changes the target-gene-regulation of FOXO3 and thereby contributes to death protection. Targeting the transcriptional activity of FOXO3 and/or the interfaces between TP53 and FOXO3 might therefore be a promising approach for the treatment of therapy-resistant NB patients with functional TP53.
MATERIALS AND METHODS

Cell lines and reagents
The NB cell lines STA-NB1, STA-NB3, STA-NB4, STA-NB8 and STA-NB15, provided by St. Anna children's Hospital, Vienna, are termed NB1, NB3, NB4, NB8 and NB15, respectively. Phoenix packaging cells for the production of retroviruses 51 and NB cells were cultured in RPMI1640 medium (Lonza, Basel, Switzerland) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St Louis, IL, USA), 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine (Lonza) in 5% CO 2 , 95% relative humidity and 37°C. HEK293T cells for the lentivirus-production were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA). All cell lines were routinely tested for mycoplasma-contamination using the Venor GeM-Mycoplasma-detection-kit (Minerva Biolabs, Berlin, Germany).
Retroviral and lentiviral expression vectors
The retroviral vectors pLIB-MCS2-iresNeo and pLIB-FOXO3(A3)-ERtm-iresNeo have been described. 5 The lentivirus-vector coding for FOXO3specific shRNA (pLKO-shFOXO3-91617-puro) and SESN3-specific shRNA (pLKO-shSESN3-141228-puro and pLKO-shSESN3-143446-puro) and the control-vector pLKO.1 were described. 3 The lentivirus-vectors coding for TP53-specific shRNA pLKO-shTP53-puro, pLKO-shTP53-941-puro and pLKO-shTP53-427-puro were provided by T. Waldmann, 52 the pGL3-Bimpromoter was provided by A. Villunger. 53 The vector pLIB-EYFP-TP53 mut-puro was generated by amplification of mutant-TP53 from NB15 cDNA (p53-fwd: 5′-GAATTCATGGATGATTTGATGC-3′; p53-rev: 5′-GGATCCT CAGTCTGAGTCAG)-3′ and inserted into the EcoR1-and BamH1-site of pLIB-EYFP-Mcl1JAM-iresPuro 54 replacing MCL1JAM by the TP53-mutant and generating pLIB-EYFP-p53m-iresPuro.
Retroviruses and lentiviruses for infection
Retroviruses and lentiviruses were produced as previously described. 
Flow cytometry
Cell death was determined by staining the cells with propidium iodide/ Triton-X100 (Sigma-Aldrich) and forward/sideward-scatter-analysis using a Beckman Coulter Cytomics FC-500 as described previously. 55 Immunoblotting and co-immunoprecipitation Preparation of total protein, cytoplasmic and nuclear fractions was described before. 3, 14 Co-immunoprecipitation was performed as described 54,56 using 1 μg of TP53-antibody, FOXO3-antibody or control-IgG and 0.5% sodiumdeoxycholate for effective nuclear lysis. Immunoblotting was done as described before. 3 Primary antibodies ( Supplementary Table S1 ) were detected with horseradish-peroxidase-conjugated secondary antibodies and chemiluminescence (GE Healthcare, Little Chalfont, UK) and analyzed using an UVP AutoChemi-detection-system.
Chromatin-immunoprecipitation
Chromatin-immunoprecipitation was performed using Magna-ChIP-Kit (Millipore, Darmstadt, Germany) as described. 6 protein-G-magnetic-beads (20 μl) were coupled to 7.5 μl of FOXO3 antibody (Santa Cruz Biotechnology, Dallas, TX, USA) or control-IgG and incubated with nuclear lysates of shredded DNA from 2 × 10 7 cells. After precipitation, protein was digested by proteinase-K and DNA was concentrated with ChIP-DNA-Clean-&-Concentrator-Kit (Zymo Research, Irvine, CA, USA). FOXO3-binding to DNA was quantified by qPCR using promoter-specific primers for FOXO3targets ( Supplementary Table S2 ).
Immunofluorescence and live cell imaging
Cells were seeded in eight-well μ-slides with glass-bottom (ibidi, Germany) coated with 0.1 mg/ml collagen. For immunofluorescence, cells were fixed with 4% ROTI-Histofix (Carl Roth, Karlsruhe, Germany) and permeabilized with 1% TritonX-100. After blocking with 1% bovine serum albumin cells were incubated with FOXO3-antibody (Cell Signaling, Boston, MA, USA), washed and incubated with anti-rabbit-AlexaFluor488 FITC-conjugated secondary antibody (Invitrogen). Nuclei were stained with 100 nM Hoechst33342 dye. For ROS-measurements, cells were incubated with Figure 7 . Proposed mechanism for the effect of functional TP53 on FOXO3-mediated drug-resistance in high-stage-derived NB. In the 'FOXO3-sensitive' subtype (NB15, NB3 cells) the mutation in the DBD of TP53 (p53mut) prevents interaction with FOXO3 during chemotherapeutic stress, so that FOXO3 steps in as tumor-suppressor and induces BIM to trigger death. This results in BIM and SESN3 induction and the pro-survival effect of SESN3 is eventually overcome by continuous accumulation of mitochondrial ROS. In the 'FOXO3-resistant' subtype (NB1, NB4, NB8), death induction via BIM is prevented by the interaction of TP53 with FOXO3. In these cells, TP53 serves as death-inducer in response to drug-treatment leading to lower basal drug resistance-but as soon as FOXO3 is activated, for example, by hypoxia or other stress signals in NB tumors, FOXO3 increases drug-protection. This mechanism might also explain the low incidence of TP53 mutations in malignant NB, as the TP53-FOXO3 interaction forces FOXO3-induced detoxification and prevents FOXO3-induced death.
FOXO3-mediated chemo-protection CM-H 2 XROS (final concentration 500 nM; Invitrogen). Images were acquired with a Zeiss Axiovert200M microscope equipped with an ApoTome.2 for structured illumination microscopy.
Quantitative RTPCR
To quantify mRNA-levels real-time qPCR was performed using Maxima-SYBR-Green-qPCR-Master-Mix (Thermo Scientific, Waltham, MA, USA) and GAPDH as reference-gene. Total-RNA was isolated from 5 × 10 6 cells using TRI-Reagent (Sigma-Aldrich). RNA (1 μg) was transcribed to cDNA using RevertAid-H-Minus-cDNA-Synthesis Kit (Thermo Scientific). Oligonucleotides for BIM, NOXA, BCLXL, BIRC5, SESN3 and GAPDH are listed in Supplementary Table S3 . qRT-PCR-reactions were performed in triplicates in a Bio-Rad-iCycler-instrument and repeated three times. After normalization to GAPDH, regulation was calculated between treated and untreated cells.
TP53-sequencing
TP53 was amplified from cDNA using oligonucleotides listed in Supplementary Table S5 . PCR-products were analyzed on 1% agarose gel and sequenced (Microsynth, Balgach, Switzerland).
Colony-formation-assay
Cells were seeded in six-well-plates and treated with 4OHT for 72 h prior to the combined treatment with doxorubicin or etoposide for another 72 h. When untreated controls reached 100% confluence colonies were fixed with ice-cold methanol, stained with 0.2% crystal violet in 50% methanol and quantified by photometry at 600 nm after discoloration with 0.5% SDS in 50% ethanol.
Spheroids
Spheroids were formed by ferromagnetic bioprinting according to the manufacturer's instructions (Pelobiotech GmbH, Planegg, Germany). When spheroids reached a size of 100 μm the cells were treated with 4OHT for 72 h prior to the combined treatment with etoposide for another 72 h. Size was monitored regularly by live-cell microscopy. ATP-amount was measured by CellTiter-Glow-3D-cell-viability-assay (Promega, Madison, WI, USA).
Statistics
Statistical significance of differences between controls and treated cells were assessed using Student's unpaired t-test or with Mann-Whitney U test (for speroids). All statistical analyses and P-values were calculated using GraphPadPrism 7.0.
